Pandion Therapeutics, Inc.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY20 | FY19 | |
|---|---|---|
| Revenue | $8.8M | $967,000 |
| Operating income | −$37.9M | −$22.2M |
| Net income | −$38.1M | −$21.9M |
| Total assets | $227.9M | $21.0M |
| Total liabilities | $13.1M | $16.8M |
| Equity | — | — |
| EPS (diluted) | — | — |
| Shares out. | 28.4M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2020- Operating margin
- −432.0%
- Net margin
- −434.0%
- Return on equity
- —
- Return on assets
- −16.7%
- Return on capital (ROCE)
- −17.3%
- Liabilities / assets
- 5.8%
- Debt / equity
- —
- Book value / share
- —
- Revenue growth (YoY)
- 807.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2020- Accruals / assets
- −1.4%clean
- Piotroski F-Score
- 5/8mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 warning● 3 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsApr 1, 2021
- Entered a material agreement · Director / officer change · Other material eventFeb 25, 2021
- Regulation FD disclosureJan 4, 2021
- Director / officer changeDec 3, 2020
- Results of operationsNov 16, 2020
- Results of operationsAug 31, 2020
- Amended charter or bylawsJul 21, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- SC 13G/AAMENDMENT NO. 1Feb 11, 2022
- SC 13G/AMay 17, 2021
- 15-12BApr 12, 2021
- SC 13D/AAMENDMENT TO FORM SC 13DApr 8, 2021
- EFFECTApr 5, 2021
- EFFECTApr 5, 2021
- SC 13D/AApr 2, 2021
- 4FORM 4 SUBMISSIONApr 1, 2021
- 4FORM 4 SUBMISSIONApr 1, 2021
- 4FORM 4 SUBMISSIONApr 1, 2021
- 4FORM 4 SUBMISSIONApr 1, 2021
- 4FORM 4 SUBMISSIONApr 1, 2021
- 4FORM 4 SUBMISSIONApr 1, 2021
- 4FORM 4 SUBMISSIONApr 1, 2021
- 4FORM 4 SUBMISSIONApr 1, 2021
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.